Brandywine Oak Private Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

Brandywine Oak Private Wealth’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-195	Closed	-$205K	–	242
2024 Q3	$205K	Hold	195	–	–	0.02%	232
2024 Q2	$205K	Buy	+195	New	+$189K	0.02%	223
2023 Q2	–	Sell	-252	Closed	-$207K	–	252
2023 Q1	$207K	Buy	+252	New	+$190K	0.02%	243
2022 Q4	–	Sell	-380	Closed	-$261K	–	286
2022 Q3	$261K	Sell	380 -3	-0.8%	-$1.89K	0.04%	224
2022 Q2	$226K	Sell	383 -66	-15%	-$42.9K	0.03%	291
2022 Q1	$313K	Sell	449 -2	-0.4%	-$1.26K	0.04%	249
2021 Q4	$284K	Sell	451 -37	-8%	-$22.7K	0.03%	260
2021 Q3	$295K	Buy	+488	New	+$303K	0.03%	258

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Brandywine Oak Private Wealth's REGN Position: Q4 2024 in Review

Brandywine Oak Private Wealth sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 195 shares — an estimated $205K sold.

Brandywine Oak Private Wealth first reported a position in REGN in Q3 2021 and held it in 8 quarters. The position peaked at $313K in Q1 2022. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Brandywine Oak Private Wealth reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Brandywine Oak Private Wealth sold 195 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $205K.
Brandywine Oak Private Wealth first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 8 quarters.
Brandywine Oak Private Wealth's Regeneron Pharmaceuticals position peaked at $313K in Q1 2022.
1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Brandywine Oak Private Wealth's 13F filing for Q4 2024, filed 27 Jan 2025.